Also known as Thymulin (distinct) · Thymus polypeptide fraction
Thymus-derived polypeptide complex — the founding tissue bioregulator (Cytomax) studied for immune restoration.
Thymalin is a polypeptide fraction extracted from calf thymus, developed by the St. Petersburg school of bioregulation as one of the original "Cytomax" tissue bioregulators. Russian clinical work studied it for restoring T-cell function in aging and immunodeficiency.
Thymalin is a peptide complex isolated from the thymus, introduced in the 1970s–80s as the prototype of the Cytomax class — animal-tissue peptide extracts intended to act as "bioregulators" of the organ they were drawn from. It is the historical anchor of the short-peptide bioregulator program later associated with Vladimir Khavinson.
Unlike the defined short peptides that followed (Epitalon, Vesugen, Pinealon), Thymalin is a heterogeneous polypeptide fraction rather than a single synthetic sequence. Reported research framed it as restoring age- or stress-depleted thymic function. The evidence base is concentrated in Russian-language clinical literature with limited independent Western replication, and it is not FDA-approved.
Reported normalization of T-lymphocyte populations and cytokine balance; tissue-specific immune regulation.
Behind every vial of Thymalin is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Thymalin, specifically, is brought into being.
Thymalin begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Thymalin is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — Thymalin plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Thymalin proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Thymalin — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing Thymalin to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Thymalin is a polypeptide fraction extracted from thymus tissue, studied in Russia as an immune-restoring "bioregulator" and regarded as the founding compound of the tissue-bioregulator class.
Thymalin is a tissue extract (a mix of polypeptides), whereas later bioregulators like Epitalon, Vesugen, and Pinealon are single, defined synthetic short peptides modeled on these extracts.
The clinical literature is concentrated in a single research tradition with limited independent replication, so findings should be treated as preliminary. This page is a research and educational reference.
No — it is a research compound and is not FDA-approved.
Synthetic tetrapeptide investigated for telomerase activity and circadian effects.
ViewSynthetic Lys-Glu dipeptide — the defined short-peptide successor to Thymalin, studied for immune and aging endpoints.
ViewSynthetic Lys-Glu-Asp tripeptide studied as a vascular-axis bioregulator.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.